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).a b s t r a c t
Biomaterial-assisted gene therapy is a promising strategy for the treatment of various musculoskeletal
disorders such as those concerning the articular cartilage, bones, tendons and ligaments, and meniscus as
it can deliver candidate gene sequences in a spatially and temporally controlled manner in sites of tissue
damage over prolonged periods of time that may be required to durably enhance the specific, natural
repair mechanisms in vivo in direct, non-invasive procedures that avoid the arduous manipulation and
implantation of patient-dependent cells genetically modified in vitro. In the present work, we provide an
overview of the most up-to-date approaches and outcomes in experimental, relevant models of such
disorders in vivo using biomaterial-guided gene transfer that may be employed in a near future to treat
patients during a clinical intervention as a means to achieve an effective, safe, and persistent trans-
lational healing of musculoskeletal injuries.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
While various clinical options are available to address muscu-
loskeletal disorders inmillions of patients worldwide [1], none thus
far has been capable of reliably regenerating the sites of tissue
damage both in their native structure and mechanical functions.
The articular cartilage, the white gliding tissue that supports
load transmission and joint mobility has a limited ability for self-
repairing the absence of vascularization that may provide regen-
erative (progenitor) cells [2]. Articular cartilage lesions like those
resulting from trauma (focal defects) or during progressive,
degenerative osteoarthritis (OA) therefore do not heal by them-
selves or following classical reconstructive surgical interventions
(marrow-stimulating techniques like microfracture, cell and tissue. Venkatesan), ana.rey.rico@
), xiaoyucai0418@gmail.com
a.fr (L. Lebeau), veronique.
.madry@uks.eu (H. Madry),
r Ltd. This is an open access articletransplantation using autologous chondrocytes or mesenchymal
stromal cells - MSCs, osteochondral cylinders) [3e5]. Despite such
treatments, the repair tissue in sites of cartilage injury is generally
of fibrocartilaginous nature (mainly type-I collagen) with poor
mechanical properties and prone to progression into secondary OA
[6,7], compared with the original hyaline cartilage composed of
type-II collagen and proteoglycans, capable of withstanding me-
chanical stress [8].
Bone tissue with a hierarchical structure (type-I collagen fibers,
nanohydroxyapatite - nHAp - matrix) to support the body weight
andmovements as points of attachment of muscles has an inherent
ability for healing but not reliably for complex, large defects or
fractures, resulting in non-unions [9]. Interventions based on au-
tografts and devitalized cadaveric allografts are still problematic,
with restricted graft availability and donor site morbidity (auto-
grafts) and inadequate tissue integration (allografts) [10].
Connective, poorly vascularized tendons and ligaments that
store elastic energy and transmit forces for locomotion [11e15] are
commonly predisposed to injuries that are critical issues in the
clinics due to the modest healing capacities of these fibrous tissues
and to their poor responses to the current therapies (sutures, auto-/
allografts, prostheses) with the formation of tissues with reducedunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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matory responses, and fibrosis [16,17].
The fibrocartilaginous, connective meniscus that transmits
weight-bearing forces promotes knee stability and proprioception,
facilitates nutrition, and allows for cartilage lubrication, is highly
susceptible to tears after trauma or related to age-associated
degenerative OA [18e23], showing no full regenerative capabil-
ities (particularly in the central avascular zone) even upon pro-
cedures of meniscal preservation, repair, and reconstruction
(partial meniscectomy, sutures, autologous tissues and allografts,
artificial substitutes) [24e28] that have several limitations (altered
biomechanical properties and structure, instability, reduced
vascularization, availability of and deleterious responses to the
graft, extrusion, cartilage degeneration, subchondral bone edema)
[23,29,30].
Gene therapy is a powerful technology to create tools for the
prolonged delivery and production of therapeutic candidate gene
sequences in musculoskeletal injuries over stable periods of time
relative to the application of recombinant gene products displaying
relatively short pharmacological half-lives (some hours)
[27,31e34]. A novel concept to ameliorate human musculoskeletal
gene therapy protocols in vivo is to provide gene-based treatments
via biomaterial-assisted procedures, allowing for a spatiotemporal,
controlled release of gene carriers and consequently of their
products in sites of musculoskeletal damage [34,35]. Such systems
may offer off-the-shelf compounds that support non-invasive,
ubiquitous (patient-independent) direct treatments in clinical
setups compared with a more complex, less convenient adminis-
tration of genetically modified cells that requires repeated patient
handling [27,31e34]. The following chapters discuss the principles
of biomaterial-assisted gene therapy and provide an overview of
translational applications for the treatment of musculoskeletal
disorders in relevant models in vivo.
2. Biomaterial-assisted gene therapy: principles
Biomaterial-assisted gene therapy is based on the delivery of
gene carriers via biocompatible, integrative, biodegradable, and
biomimickingmaterials employed in tissue engineering procedures
as a means to provide biological cues and support the endogenous
reparative mechanisms in damaged musculoskeletal tissues by
offering a cell-supporting scaffold in sites of injury [36e39].
2.1. Biomaterials for musculoskeletal applications
Various biomaterials have been manipulated in musculoskeletal
research such as hydrogels and solid scaffolds derived from natural
or synthetic materials (or from both) and displaying specific fea-
tures to mimic the architecture and properties of the extracellular
matrix (ECM) of the tissues, with both advantages and shortcom-
ings for musculoskeletal repair [8,27,40e67].
Hydrogels are three-dimensional (3D) cross-linked polymer
networks with a hydrophilic structure that makes them capable of
holding large amounts of water for swelling (but without dissolu-
tion in water), being permeable to oxygen and nutrients [68]. They
are biocompatible, easy to fabricate under mild conditions, and can
be tailored and provided in a minimally invasive manner in tissue
lesions of any size by arthroscopy as they can be provided as
injectable formulations [69e71]. Natural hydrogels with a higher
biocompatibility and biodegradability have been largely applied in
translational tissue engineering strategies to treat injuries of the
articular cartilage, bone, tendons/ligaments, and meniscus, based
on fibrin, hyaluronic acid (HA), chitosan, collagen, peptides, gelatin,
and alginate [72e86]. Synthetic hydrogels have more reproducible
properties and they can be manipulated as “smart” systems to2
respond to a variety of environmental stimuli (pH, temperature,
ionic strength, inflammation, etc) [87] and have been also
employed in musculoskeletal tissue engineering using poly-
ethylene glycol (PEG), polyacrylamide (PAM), polyvinyl alcohol
(PVA), poly(lactic acid) (PLA), poly(lactide-co-glycolide) (PLGA),
self-assembling peptides, poly(N-isopropylacrylamide) (pNIPAAm),
polyethylene oxide- (PEO-) and polypropylene oxide- (PPO-) based
copolymers (poloxamers or Pluronic®, poloxamines or Tetronic®),
poly(ε-caprolactone) (PCL), HAp, and beta-tricalcium phosphate (b-
TCP) [88e97] or mixed with natural compounds for the same
purposes [98e104]. On the other side, hydrogels display lesser
mechanical properties relative to solid scaffolds.
Mechanically stable solid scaffolds are well adapted to treat le-
sions affecting the musculoskeletal tissues as these are composed
of a dense ECM exposed to external loads that lead to tissue
deformation and/or strains. Solid scaffolds may be created with
natural polymers such as HA, chitosan, collagen, gelatin, and silk
[105e120] or using synthetic materials like PLA, poly-glycolic acid
(PGA), PLGA, PEG, PCL, polyurethane (PU), HAp, b-TCP, poly(-
propylene fumarate) (PPF), polyhydroxyalkanoates (PHA), bioactive
glasses, titanium, and polyethylene terephthalate [121e142] that
may be further mixed with natural compounds [143e148]. Solid
scaffolds can be also combined with hydrogels to produce hybrid
scaffolds (or composites) based on fibrinwith either PU, PCL, b-TCP,
or collagen, on alginate with PLA, PLGA, or b-TCP, on collagen with
b-TCP, on agarose/PEG with PCL, on self-assembling peptides and
PCL, and on pluronic F127 with b-TCP [149e161].
2.2. Gene therapy
Gene therapy consists in (i) the transfer of exogenous nucleic
acid sequences (transgenes) in target cells or (ii) the endogenous
editing of the genome of target cells for instance using the clustered
regularly interspaced short palindromic repeats (CRISPR)/CRISPR-
associated protein-9 nuclease (Cas9) system, both using a gene
carrier (vector) derived from nonviral systems or viruses (Table 1)
[31e34,162e167].
Nonviral vectors avoid the risk to acquire replication compe-
tence specific of virus-derived vectors and do not activate immune
responses in a recipient, making them safe gene carriers for in vivo
applications. Yet, they are associated with low and short-term gene
transfer efficiencies (some days) while necessitating cell division to
permit gene nuclear translocation that occurs only in very few cell
populations at the adult stage [168], making themmore suitable for
ex vivo (indirect) gene therapy procedures by transplantation of
genetically modified cells. Viral vectors produced in musculoskel-
etal research from adenoviruses, retro-/lentiviruses, and adeno-
associated virus (AAV) use natural entry pathways in target cells,
with features inherent to each virus class. Adenoviral vectors
permit high gene transfer efficiencies and therefore in vivo (direct)
gene therapy approaches, but they are very immunogenic, rela-
tively unsafe, and shortly effective (some days to a 1e2 weeks)
[169]. Retro-/lentiviral vectors that have the ability to integrate in
the genome of host cells may be durably functional. However, they
have a relatively lowgene transfer efficiency that makes themmore
adapted for ex vivo (indirect) gene therapy strategies while neces-
sitating cell division (except for lentiviral vectors that originate
from the pathogenic human immunodeficiency virus - HIV) and
possibly activating tumor genes upon integration [170,171]. Re-
combinant, gutless AAV (rAAV) vectors are safe gene vehicles that
are maintained under stable episomal forms in the targets and
allow for high, prolonged gene transfer efficiencies (months to
years) that support in vivo (direct) gene therapy settings [35,172].
Despite the value and versatility of gene transfer vectors, their
optimal use for musculoskeletal gene therapy in the clinics
Table 1
Gene transfer vectors commonly used in musculoskeletal research.
Vectors Advantages Limitations Maintenance
Nonviral vectors . Not infectious
. Not immunogenic
. Low, short-term efficiency
. Cell division needed
episomal
Adenoviral vectors . High efficiency




Retro-/lentiviral vectors . Long-term efficiency . Low efficiency
. Cell division needed (not for lentiviral vectors)
. Insertional mutagenesis
integration
rAAV vectors . High, long-term efficiency




rAAV: recombinant adeno-associated virus.
Fig. 1. Principle of biomaterial-assisted gene therapy for musculoskeletal regenerative
medicine. Candidate non-viral and viral gene transfer vectors may be incorporated into
biomaterial scaffolds that act as reservoirs to provide a spatially and temporally
defined vector-controlled delivery and release in sites of musculoskeletal tissue
damage (bone, cartilage, meniscus, tendon/ligament) over prolonged periods of time.
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that hinder their effective translational application. First, the vectors
may disseminate to non-target organs and be cleared from the body
[173,174]. Next, their access to the targets might be blocked by
physical and biological barriers such as body fluids (synovial fluid),
blood binding factors, adverse microenvironment (pH, hypoxia,
enzymatic and inflammatory molecules), dense ECM components,
and/or inhibitory clinical compounds (heparin) [175,176]. Finally,
the vectorsmay raise toxic and (patient-specific) immune responses
counteracting their efficacy (neutralizing antibodies and cellular
immunity against the viral capsid proteins) [177e182] and have a
low and short-term efficacy. Current strategies to address these is-
sues include the transient immunosuppression of the host [183], a
plasmapheresis and saline flushing [184], the use of alternative
clinical compounds (hirudin) [175,176,185], and the genetic engi-
neering of the viral vector capsid (chemical modification, epitope
insertion, use of decoys, pseudotypes, hybrids, variants, mosaic/
chimeric/mutant vectors) [186e193]. However, these strategies are
either toocomplexand invasive, technologicallyarduous, orpatient-
specific, and have notmet success in clinical setups yet, showing the
critical need for new avenues of research that might more conve-
niently lead to systems applicable to all patients in clinical protocols.
2.3. Biomaterial-assisted gene therapy: controlled gene vector
delivery
Combining gene therapy and tissue engineering procedures is a
promising concept to overcome such hurdles by using a biomaterial
as a cargo (or gene-activated matrix) to deliver a gene transfer
vector in sites of musculoskeletal damage [34,35,194e200], based
on the development of controlled drug delivery tools [201e203].
The controlled delivery and release of gene vectors from a bioma-
terial may: (1) enhance their spatial and temporal presentation and
residence time in their targets; (2) minimize the doses of vector
applied and prevent its dissemination; (3) provide stability against
premature vector degradation; and (4) mask viral capsid epitopes
to afford protection against immune responses. Gene vectors may
be amenable to scaffold-mediated delivery upon encapsulation
(loading during the preparation of the scaffold) or immobilization
(adsorption on a scaffold formed beforehand) to allow for a
gradient polymeric or substrate-mediated release, respectively,
using hydrogels (vector diffusion process) or solid scaffolds (vector
transfer from the substrate). Alternatively, the vector may be pro-
vided to the scaffold using bioprinting tools in defined 3D patterns
[200,204].
3. Biomaterial-assisted gene therapy: applications for
musculoskeletal disorders
Several experimental approaches using biomaterial-assisted
gene therapy procedures have been reported in clinically relevant3
experimental models to develop treatments for disorders of the
musculoskeletal system (Fig. 1 and Tables 2 and 3).3.1. Articular cartilage
Micelles based on poloxamers and poloxamines have been
employed to enhance the chondrogenesis of MSCs via delivery of
rAAV vectors coding for the cartilage-specific sex-determining re-
gion Y-type high mobility group box 9 (SOX9) transcription factor
in vitro with an increased deposition of ECM compounds (pro-
teoglycans, type-II collagen), further affording protection against
rAAV gene transfer inhibitors (viral uptake interfering agents such
as heparin, anti-AAV capsid neutralizing antibodies) [205,206] and
to heal experimental osteochondral defects by transfer of rAAV
vectors carrying either SOX9 or the transforming growth factor beta
(TGF-b) in explant cultures in situ by increasing the proliferative,
pro-anabolic, and anti-hypertrophic activities in local chondrocytes
(enhanced proteoglycan and type-II collagen deposition, reduced
type-X collagen expression and mineralization) [207,208]. Carbon
dot formulations have been also prepared to deliver rAAV vectors
coding for SOX9 or TGF-b as a means to stimulate MSC chondro-
genesis in vitro by enhancing cell proliferation and ECM deposition
(glycosaminoglycans, type-II collagen) while containing undesir-
able osteogenesis and terminal differentiation (type-I and -X
collagen deposition [209].
Table 2
Biomaterial-assisted gene therapy in musculoskeletal research: articular cartilage.







Formulations rAAV carbon dots SOX9, TGF-b MSCs [209]
Hydrogels NV HA luc MSCs [210,212]
PEG, OPF luc MSCs [211]
OPF SOX trio, RUNX2 OCD [214]
pNIPAAm luc MSCs [213]
alginate/HAp TGF-b, BMP-2 MSCs [215]
rAAV fibrin TGF-b MSCs [216]
SALPs lacZ, RFP MSCs [218]
alginate, poloxamers lacZ MSCs [217]
poloxamers, poloxamines SOX9 CD [220]
polypseudorotaxanes lacZ MSCs [219]
Solid scaffolds NV chitosan, gelatin TGF-b ACs [222]
chitosan, gelatin, HAp TGF-b, BMP-2 OCD [226]
collagen IGF-I ACs [223]
endostatin MSCs [225]
collagen, GAG luc ACs [221]
IGF-I ACs [224]
PLGA SOX trio OCD [227]
LV PCL TGF-b MSCs [228]
IL-1Ra MSCs [229,230]
iPSCs [231]
rAAV PCL lacZ, RFP BMA [232]
SOX9 BMA [233]
Hybrid scaffolds NV fibrin, PLGA TGF-b OCD [234e236]
rAAV: recombinant adeno-associated virus; NV: nonviral vectors; LV: lentiviral vectors; HA: hyaluronic acid; PEG: polyethylene glycol; OPF: oligo(poly(ethylene glycol)
fumarate); pNIPAAm: poly(N-isopropylacrylamide); HAp: hydroxyapatite; SALPs: self-assembling peptides; GAG: glycosaminoglycan; PLGA: poly(lactide-co-glycolide); PCL:
poly(ε-caprolactone); SOX9: sex-determining region Y-type high mobility group box 9; lacZ: E. coli b-galactosidase; TGF-b: transforming growth factor beta; luc: Firefly
luciferase; SOX trio: SOX5, SOX6, SOX9, RUNX2: runt-related transcription factor 2; BMP-2: bone morphogenetic protein 2; RFP: red fluorescent protein; insulin-like growth
factor I; IL-1Ra: interleukin-1 receptor antagonist; MSCs: mesenchymal stromal cells; eOCD: experimental osteochondral defect; CD: chondral defect; ACs: articular chon-
drocytes; iPSCs: induced pluripotent stem cells; BMA: bone marrow aspirates.
Table 3
Biomaterial-assisted gene therapy in musculoskeletal research: bone.
Systems Vectors Biomaterials Genes Models Ref.
Hydrogels NV alginate, collagen SOX9 MSCs [240]
alginate, HAp TGF-b, BMP-2 MSCs [239]
LV gelatin BMP-2 MSCs [241]
Solid scaffolds NV chitosan lacZ MSCs [243]
collagen BMP-4, PTH [1e34] FD [242]






collagen, HAp luc MSCs [256]
BMP-2 MSCs [255,259]
VEGF MSCs [259]
collagen, PGA BMP-2 MSCs [248e250]
gelatin, PGA BMP-2 MSCs [245]
gelatin, collagen BMP-2 MSCs [245]
gelatin, collagen, PGA BMP-2 MSCs [245]
PCL RUNX2 MSCs [257]
PLGA TGF-b MSCs [258]
TGF-b FD [258]
PLLA, PLGA GFP MSCs [253]
Ti BMP-2 MSCs [260]
Ti, PDLLA BMP-2 MSCs [254]
AdV b-TCP RUNX2 FD [261]
rAAV PCL BMP-2 MSCs [262]
BMP-2 FD [262]
PLLA BMP-2 MSCs [263]
NV: nonviral vectors; LV: lentiviral vectors; AdV: adenoviral vectors; rAAV: recombinant adeno-associated viral vectors; HAp: hydroxyapatite; PGA: poly-glycolic acid; PCL:
poly(ε-caprolactone); PLGA: poly(lactide-co-glycolide); PLLA: poly-L-lactide acid; Ti: titanium; PDLLA: poly(d,L-lactide); b-TCP: beta-tricalcium phosphate; SOX9: sex-
determining region Y-type high mobility group box 9; TGF-b: transforming growth factor beta; BMP: bone morphogenetic protein; lacZ: E. coli b-galactosidase; PTH
[1e34]: parathyroid hormone (amino acids 1e34); GFP: green fluorescent protein: VEGF: vascular endothelial growth factor; luc: Firefly luciferase; RUNX2: runt-related
transcription factor 2; MSCs: mesenchymal stromal cells; FD: femoral defect; TD: tibial defect; RD: radial defect.
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rAAV vectors [216e220] using fibrin [216], HA [210,212], PEG and
derivatives [211,214], pNIPAAm [213], self-assembling peptides
[218], poloxamers and poloxamines [220], polypseudorotaxanes
[219], and alginate with poloxamers [217] or with HAp [215] to
transfer sequences for reporter genes [210e213,217e219] (Fig. 2) or
for therapeutic SOX9 and the SOX trio (SOX5, SOX6, SOX9)
[214,220], TGF-b [215,216], bone morphogenetic protein 2 (BMP-2)
[215], and bone-specific runt-related transcription factor 2
(RUNX2) [214] as a means to activate MSC chondrogenesis in vitro
[210e213,215e219] and to enhance the repair of focal cartilage
defects in vivo [214,220]. For instance, moderate levels of transgene
expression with release profiles of ~10 days were observed when
incorporating plasmid DNA coding for luciferase (luc) gene/poly-
plexes into microporous hydrogel systems [210,212] and additional
incorporation of micelles in hydrogel systems increased gene
expression relative to hydrogel systems alone [211]. In addition, a
bilayered porous oligo[PEG fumarate] hydrogel employed to co-
deliver plasmid sequences coding for the chondrogenic (SOX trio)
and osteogenic (RUNX2) transcription factors via poly(-
ethylenimine)/HA complexes improved the healing of rat osteo-
chondral defects relative to single gene delivery and to empty
hydrogel systems [214]. Besides, release of an rAAV gene vehicle
coding for TGF-b(1) from a fibrin glue scaffold had strong beneficial
effects on the expression of cartilage-specific gene in MSCs [216].
Also, incorporation in and release of rAAV vectors from alginate/
poloxamer (PF127) systems allowed to support elevatedFig. 2. Targeting of human mesenchymal stromal cells via alginate-assisted rAAV-mediated
spheres concomitantly with an rAAV vector carrying either the reporter gene coding for th
fluorescent protein (RFP), i.e. rAAV-RFP (top panel). Images (bottom panels) reveal the effect
expression detected by X-Gal staining, magnification x20; right: RFP expression visualized
5
transduction efficiencies in MSCs without detrimental effects on
the chondrogenic differentiation potential and viability of these
cells in vitro [217]. Furthermore, controlled release of rAAV from
self-assembling peptide hydrogels RAD16-I in a pure (RAD) form or
combined with HA (RAD-HA) led to the successful genetic modifi-
cation of MSCs without altering their viability nor chondrogenic
commitment [218]. Next, delivery of rAAV vectors via supramo-
lecular polypseudorotaxane gels was capable of promoting higher
gene transfer efficiencies and cytocompatibility in MSCs compared
with free vectors [219]. Most strikingly, overexpression of an rAAV
SOX9 gene vehicle via in situ controlled release from a PEO-PPO-
PEO hydrogel led to superior cartilage repair in full-thickness
minipig chondral defects in vivo compared with hydrogel-free
vector delivery [220].
Solid scaffolds have been also prepared to deliver non-viral
[221e227], lentiviral [228e231], and rAAV vectors [232,233] using
chitosan with gelatin [222] or with gelatin and HAp [226], collagen
[223,225] with glycosaminoglycan (GAG) [221,224], PLGA [227],
and PCL [228e233] to transfer sequences for reporter genes
[221,232] or for therapeutic SOX9 and SOX trio [227,233], TGF-b
[222,226,228], BMP-2 [226], insulin-like growth factor I (IGF-I)
[223,224], interleukin-1 receptor antagonist (IL-1Ra) [229e231],
and the anti-angiogenic endostatin factor [225] in order to target
articular chondrocytes in vitro [221e224], stimulate chondrogenic
and anti-inflammatory events in MSCs [225,228e230], in induced
pluripotent stem cells (iPSCs) [231], and in bone marrow aspirates
[232,233] in vitro (Fig. 3), and promote the repair of focal cartilagegene transfer. Human mesenchymal stromal cells (MSCs) were encapsulated in alginate
e E. coli b-galactosidase (lacZ), i.e. rAAV-lacZ, or the reporter gene coding for the red
ive gene transfer and transgene expression in the treated MSCs after 10 days (left: lacZ
under fluorescent microscopy, magnification x10).
Fig. 3. Therapeutic PCL-assisted rAAV-mediated gene transfer in human bone marrow aspirates in situ. PCL films were coated with rAAV (therapeutic rAAV-TGF-b vector carrying
the highly chondrogenic transforming growth factor beta - TGF-b - vs. reporter rAAV-lacZ) and next incubated with human bone marrow aspirates. Images reveal the effective gene
transfer and transgene (TGF-b) expression in aspirates treated with PCL/rAAV-TGF-b relative to PCL/rAAV-lacZ after 21 days (magnification x10) (top panels) and the increased
deposition of cartilage matrix components (proteoglycans by toluidine blue staining, left; type-II collagen expression by immunohistochemical detection, right) in response to PCL/
rAAV-TGF-b application vs. PCL/rAAV-lacZ after 21 days (magnification x10) (bottom panels).
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use of a type-II collagen-glycosaminoglycan (CG) scaffold as a non-
viral system to deliver the gene for IGF-I to support cartilage repair.
Sustained levels of IGF-I expression using such a setup significantly
promoted cartilage tissue formation with chondrocyte-like cells,
GAG accumulation, and type II-collagen deposition relative to
control treatments lacking IGF-I. More recently, the same group
monitored the effects of modifying the charge of a gelatin delivery
system by cationization to deliver an IGF-I-coding plasmid as a
means to genetically modify articular chondrocytes [224]. The
result of the study revealed a 5-fold difference of IGF-I expression
between groups treated with cationized particles compared with
non-cationized ones. Transfection of cells seeded in type-II
collagen-glycosaminoglycan (CG) scaffolds via cationized gelatin
particles resulted in 60% higher GAG/DNA contents vs. untreated
chondrocytes or chondrocytes transfected with gelatin alone. Also
interestingly, implantation of a bilayered gene-activated osteo-
chondral matrix consisting of both a plasmid TGF-b1-activated
chitosan-gelatin scaffold (chondrogenic layer) and a plasmid
BMP-2-activated HAp/chitosan-gelatin scaffold (osteogenic layer)
in rabbit osteochondral defects led to concomitant cartilage and
subchondral bone repair with good integration of the system with
the native osteochondral tissues [226]. Besides, the group of Guilak
et al. [228] demonstrated that delivery of a lentiviral vector coding
for TGF-b3 via immobilization on PCL films led to the successful6
transduction of MSCs that produced a robust ECM in response to
therapeutic (TGF-b3) transgene expression. The same group
[229,230] further reported that administration of a lentiviral
construct promoting the expression of IL-1Ra in a doxycycline
(dox)-inducible manner via 3D woven PCL scaffold allowed for the
production of a cartilage-specific ECM in MSCs in the presence of
pathologic levels of IL-1 [229] and joint resurfacing in anatomically
shaped cartilage constructs engineered with adipose-derived MSCs
[230]. This group also showed that delivery of a nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB)-inducible
lentiviral vector coding for IL-1Ra inhibited pro-inflammatory
pathways and ECM degradation in iPSC-based constructs treated
with IL-1 [231]. Of further note, recent evidence showed the ben-
efits of using PCL films grafted with poly(sodium styrene sulfonate)
(pNaSS) as novel, highly effective systems for the controlled de-
livery of rAAV vectors to reparative bone marrow aspirates
[232,233], allowing to enhance the biological activities and chon-
drogenic processes in the samples (ECM deposition) when deliv-
ering an rAAV SOX9 construct compared with the release of control
(reporter) rAAV vectors or when using ungrafted films [233].
In addition, hybrid scaffolds composed of fibrin and PLGA were
also used to carry nonviral vectors coding for TGF-b as systems to
enhance the repair of focal cartilage defects in vivo [234e236]. For
instance, Wang et al. [234] reported that a TGF-b-gene activated
matrix based on fibrin/PLGA scaffolds seeded with MSCs enhanced
Fig. 4. Therapeutic PCL-assisted rAAV-mediated gene transfer in focal cartilage defects in vivo. PCL scaffolds were coated with rAAV (therapeutic rAAV-SOX9 vector carrying the
highly chondrogenic cartilage-specific sex-determining region Y-type high mobility group box 9 transcription factor - SOX9 - vs. reporter rAAV-lacZ) and next applied to full-
thickness chondral defects in minipigs after microfracture in the presence of bone marrow aspirate. Images reveal the effective gene transfer and intracellular transgene (SOX9)
expression in the defects treated with PCL/rAAV-SOX9 relative to PCL/rAAV-lacZ after 4 weeks (magnification x20) and the increased deposition of cartilage matrix components
(proteoglycans by safranin O staining, top; type-II collagen expression by immunohistochemical detection, bottom) in response to PCL/rAAV-SOX9 application vs. PCL/rAAV-lacZ
after 4 weeks (magnification x4).
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fects in rabbits comparedwith the use of empty scaffolds. Of further
note, complexation of a TGF-b-coding plasmid via PEO-b-poly (L-
lysine) (PEO-bPLL) [235] or Lipofectamine [236] further increased
the performance of these hybrid materials.
Of note, no studies are currently available on the potential of
biomaterial-assisted gene therapy for the treatment of OA,
although it has been evoked in recent reviews of the literature
[200,237,238].7
3.2. Bone
Hydrogels have been employed to deliver non-viral [239,240]
and lentiviral vectors [241] using gelatin [241] and alginate with
collagen [240] or with HAp [239] to transfer SOX9 [240], TGF-b
[239], and BMP-2 [239,240] as a means to stimulate MSC osteo-
genesis in vitro [239e241]. Cunniffe et al. [239] developed a gene-
activated bioink using RGD-g-irradiated alginate and nHAp com-
plexed to plasmid DNA and combined it with PCL and MSCs to
Fig. 5. Principle of therapeutic PCL-assisted rAAV-mediated gene transfer in injured
ligaments. PCL fibers may be coated with rAAV (therapeutic rAAV-FGF-2 vector car-
rying the reparative basic fibroblast growth factor - FGF-2 - vs. reporter rAAV-lacZ) for
application to ligament lesions like those affecting the anterior cruciate ligament (ACL).
The figure shows the principle of the approach in a model of ACL lesion in vitro
experimentally created with a scalpel. Healing may be monitored by evaluating the
effects of the treatment on the extent (length, depth, 3D area) of the lesion.
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of genes coding for BMP and TGF-b from these constructs promoted
a robust osteogenesis of encapsulated MSCs in vitro. When subcu-
taneously implanted in nude mice, these gene-activated matrices
enhanced vascularization and mineralization compared with cell-
free controls. In another attempt, collagen-I-alginate inter-
penetrating polymer network hydrogels were created to generate
gene-activated matrices with nanocomplexed SOX9 poly-
nucleotides and MSCs [240]. The results of the study demonstrated
that SOX9 effectively inducedMSC chondrogenesis and reduced the
expression of hypertrophy markers compared with control
matrices.
Solid scaffolds have been also prepared to deliver non-viral
[194,242e260], adenoviral [261], and rAAV vectors [262,263] us-
ing chitosan [243], collagen [194,242,244,246,247,251,252] with
HAp [255,256,259] or with PGA [248e250], gelatin with collagen,
PGA, or both [245], b-TCP [261], PCL [257,262], poly-L-lactide acid
(PLLA) [263] or PLGA [258] or both [253], or titanium and de-
rivatives [254,260] as means to transfer sequences for reporter
genes [243,246,251,253,256] or for therapeutic TGF-b [258], BMP-2
[245,247e250,254,255,259,260,262,263] and BMP-4 [242], RUNX2
[257,261], parathyroid hormone (amino acids 1e34) (PTH [1e34])
[194,242], and vascular endothelial growth factor (VEGF)
[244,252,259] in order to activate MSC osteogenesis in vitro
[243,245,248e251,253e260,262,263] and to heal bone defects
in vivo [194,242,244,246,247,252,258,261,262]. Hosseinkhani et al.
[245] impregnated a complex of cationized gelatin and plasmid
DNA coding for BMP-2 in PGA fiber fabrics, collagen sponges, or
collagen sponges reinforced by the incorporation of PGA fibers.
Alongisde, the authors compared the levels of transgene expres-
sion obtained upon incorporation of MSCs in the different con-
structs under static, stirring, or perfusion culture conditions [249].
The results of the evaluation showed a more sustained release
profile of plasmid DNA upon incorporation in PGA-reinforced
sponges vs. other scaffolds and increased levels of B MP-2
expression via perfusion [245,249]. When the constructs were
subcutaneously implanted in rats, higher levels of alkaline phos-
phatase (ALP) and osteocalcin expression were noted compared
with groups impregnated or processed with the other methods
[248]. Similar results were observed when incorporating plasmid
BMP-2 DNA-nanoparticles using the same PGA-reinforced sponges
[250]. In another study, a collagen-nHAp gene-activated matrix
was developed by incorporating a plasmid BMP-2 DNA and MSCs
[255]. In this work, enhanced osteogenesis in the cells was
observed following nHAp-BMP-2 transfection both in 2D and 3D
cultures at low levels of plasmid BMP-2 DNA. Dual delivery of
plasmid BMP-2 DNA and plasmid VEGF DNA from the same con-
structs markedly promoted bone healing upon implantation in rat
transosseous defects [259]. Other interesting work showed that
release of an adenoviral vector carrying the coding sequence for
the core-binding factor subunit alpha-1 (Cbfa1) from b-TCP/
osteoprogenitor cells promoted bone formation upon subcutane-
ous implantation in rat bone defects [261]. Dupont et al. [262] also
provided evidence that a self-complementary AAV (scAAV) vector
coding for BMP-2 coated on 3D porous poly(ε-caprolactone) (PCL)
scaffolds seeded with bone marrow- or amniotic fluid-derived
mesenchymal stromal cells (MSCs) permitted increased mineral
formation and bony bridging with stronger mechanical properties
when implanted in critically sized immunocompromised rat
femoral defects. Such findings corroborated work from Xue et al.
[263] showing that an rAAV vector coding for BMP-2 encapsulated
in a PLLA scaffold loaded with MSCs promoted bone formation
when administered to an ectopic mouse model in vivo (muscle
implantation).8
3.3. Other musculoskeletal tissues
Interestingly, such approaches have not been reported yet to
heal lesions affecting the tendons, ligaments, or meniscus, but they
have been evoked in recent reviews of the literature [27,199]
(Fig. 5).4. Conclusions and perspectives
Several experimental studies in clinically relevant animal
models in vivo currently validate the concept of biomaterial-
assisted gene therapy to activate the repair processes in musculo-
skeletal tissues including the articular cartilage and bone andmight
further be envisaged to treat tendon, ligament, and meniscal le-
sions. Compared with the delivery of recombinant growth factors
that exhibit very short half-lives and may be associated with
adverse effects when used at high, supraphysiological doses [202],
biomaterial-guided gene therapy may provide transgene expres-
sion profiles of therapeutic factors in a sustained, but controlled
delivery manner by direct transfer of the candidate gene sequences
in sites of tissue damage. Yet, even though numerous protocols
have been conducted in patients using gene therapy [34,264,265]
including for orthopedic applications [33,266e271], as well as tis-
sue engineering approaches [25,47,50,57], there is only one clinical
trial thus far reporting the feasibility of combining these two pro-
cedures by delivering a nonviral vector coding for VEGF via a
collagen/HAp sponge for the treatment of mandibular bone defects
in patients [272].
While gene-based translational applications are arduous, costly,
and viewed as unsafe [265,273,274], the scarcity of biomaterial-
assisted gene therapy trials may also reflect a need for more
comprehensive experimental work to define optimal, i.e. effective/
safe/non-immunogenic therapeutic compounds. This requires to
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scaffold (hydrogels, solid scaffolds, hybrid materials), and gene
(anti-inflammatory molecules, growth factors, transcription fac-
tors, signaling agents, etc.; individual vs. combined genes; genes
that might be highly specific for the cartilage or for the bone to
prevent unwanted effects in the adjacent/underlying tissue), the
optimal level and duration of transgene expression and the most
adequate control element/promoter (high level, tissue-specific, or
disease-regulatable expression), as well as the route/occurrence of
administration to avoid unwanted dissemination of the vectors to
non-target locations (intra-articular injection, arthroscopy,
arthrotomy; single vs. repeated administration). Other important
points to consider include the manufacturing of vectors and of
materials suitable for clinical applications (origin, clinical-grade
nature, ease of fabrication, scalability, storage, pharmacokinetic
release profiles, cost-effectiveness) that might be capable of
penetrating dense tissues such as the articular cartilage and the
bone prior to obtaining approval from regulatory agencies
[275e278].
It remains to be seen how integrating scaffold/gene vector
systems with the use of 3D bioprinting techniques that mimic
structural features of the targeted injured tissue [204,239,279] or
with that of orthobiologics (platelet-rich plasma - PRP, extra-
cellular vesicles - EVs, etc. ) as a personalized, biological
augmentation/enrichment/adjuvant method [65,280e284] may
be of added value for improved musculoskeletal therapy.
Furthermore, the alternative translational use of innovative
genome editing tools like those based on the Clustered regularly
interspaced short palindromic repeats (CRISPR)/ CRISPR-associ-
ated protein-9 nuclease (Cas9) technology relative to classical
(trans)gene therapy will require to expand our current knowl-
edge on the benefits of such an approach in the musculoskeletal
research area, as thus far only on study demonstrated the pos-
sibility to contain cartilage degeneration via rAAV-mediated
editing of IL-1b and MMP-13 in experimental OA mice in vivo
in a scaffold-free setup [285], aside from work showing the po-
tential of CRISPR/Cas9 to preserve or rejuvenate MSCs and
chondrocytes and to provide OA study models in vitro
[286e294]. The effective and safe clinical use of CRISPR-Cas9 for
genome manipulation will also necessitate a thorough benefit-
risk assessment for musculoskeletal regenerative medicine
compared with current clinical treatments for non-lethal or-
thopedic disorders and as this technology still faces a number of
critical issues and challenges for adapted translation in patients
(reproducibility, variability, off-target effects, immune responses
against bacterial Cas9, existence of natural Cas9 inhibitors, effi-
ciency in vivo, etc. ) [295,296].
In conclusion, biomaterial-assisted gene therapy may provide
adapted, novel tools as off-the-shelf systems that might be
employed in conjunction with traditional clinical interventions for
non-invasive treatments of musculoskeletal disorders in patients in
near future by cooperation between scientists and clinicians and
with the assistance and control of regulatory agencies.
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